is comparatively low ( Table 1) . Most of patients need long-term medication. Maintained long term response rate is also low after cessation of antiviral therapy. Prolonged usage of NUC in the treatment of CHB patients is well tolerated, but the drug resistance merged at a high rate. Monotherapy using theses drugs in the antiviral therapy of CHB patients is therefore limited. To improve the efficacy of antiviral therapy for CHB patients, combination of different antiviral drugs is an important method, including combination of NUC drugs and NUC drugs (without cross resistance) or NUC drugs and IFN-α (different antiviral mechanism). Combination therapy using drugs with different mechanisms may improve the efficacy of antiviral therapy. Combination therapy using NUC drugs without cross resistance may reduce drug resistance.
Concept and types of antiviral combination therapy for chronic hepatitis B
Antiviral combination therapy of chronic hepatitis B is the strategy of application of two or more antiviral drugs in treatment of CHB. Currently, seven drugs have been approved to treat chronic hepatitis B, including two formulations of interferonα (conventional IFN-α and PEG-IFN) and five nucleos(t)ide analogues (lamivudine, adefovir dipivoxil, entecavir, telbivudine and tenofovir dipivoxil). Simultaneous or sequential uses of any two or more drugs are belongs to antiviral combination therapy of chronic hepatitis B. According to the start time point of clinical treatment of antiviral combination therapy, there are three types of antiviral combination therapy, such as de novo combination therapy, optimized combination therapy and rescue combination therapy ( Figure 1 ).
Therapeutic options of antiviral combination therapy for chronic hepatitis B Combination of NUC drugs and NUC drugs for CHB De novo combination therapy
At present, it is thought that de novo combination therapy is not suitable for all CHB patients. The disease progression and clinical feature should be taken into consideration. The latest evidence indicated that patients with high baseline HBV DNA levels, decompensate liver cirrhosis, or co-infection of HBV DOI: 10.1515 DOI: 10. /ii-2017 and HCV or HBV and HIV should be treated with the strategy of de novo combination therapy. a. Indications: Patients with baseline HBV DNA≥8 log 10 IU/ml, or with decompensate liver cirrhosis should be recommended to de novo combination therapy or NUC monotherapy, and the drug of high potency and low resistance is preferred. Studies have shown that the rate of HBV DNA under the limit of detection was low and the incidence of resistance was high in patients with higher baseline HBV DNA levels treated with LdT or LAM. 4, 5 De novo combination therapy could improve the efficacy and reduce resistance risk. 6 Patients with higher baseline HBV DNA levels should start treatment with de novo combination therapy or with drugs of high potency and low resistance (ETV or TDF) in NUC monotherapy. Patients with decompensate liver cirrhosis usually need long-term antiviral treatment, drugs of high potency and low resistance is preferred, or de novo combination therapy using drugs of less potency or higher drug resistance in order to get efficient inhibition of HBV and reduce the risk of resistance. 7, 8 b. Medication: The main principle of combination of different NUC drugs for CHB patients is to avoid cross resistance. In a phase Ⅱ clinical study, one-year treatment of telbivudine monotherapy, lamivudine monotherapy, and the combination therapy with these two drugs for patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B showed that the combination regimens were similar Treatment response parameters  Approved therapies  LAM  ADV  ETV  LdT  TDF  PegIFN  HBeAg-positive patients at week 48 or 52  Undetectable HBV DNA  40-44  21  67  60  76  25  HBeAg seroconversion  16-21  12  21  22  21  27  HBsAg loss  < 1  0  2  0  3  3  HBeAg-positive patients during extended 
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Optimized combination therapy Several studies indicated that the use of the roadmap concept could improve outcomes of chronic hepatitis B patients, including improvement of antiviral efficacy and reduction of resistance incidence in patients treated with NUC monotherapy. 11,12 Combination therapy should be considered for patients who treated with NUC monotherapy and the response was suboptimal. a. Patients treated with NUC monotherapy should be evaluated at week 12. The levels of serum HBV DNA decreased less than 2 log 10 copies/ml from baseline should be changed to combination therapy. Addiction with another NUC drugs without cross resistance or switch to more potent antiviral drugs is necessary. b. HBV DNA level should be detected at the time point of week 24. The responses could be divided into complete response, partial response and inadequate response according to the levels of serum HBV DNA at week 24. The patients with complete virological response (defined as undetectable HBV DNA levels) may continue treatment with the same agent, and then the frequency of follow-up can be prolonged to six months.
The extend strategies of patients with partial virological response (3 log 10 copies/ml < HBV DNA< 4 log 10 copies/ml) are variable depending on the varieties of drugs for initial treatment.
The patients receiving drugs with a low genetic barrier to resistance (e.g. lamivudine) should be considered to add another drug without cross resistance (adefovir dipivoxil or tenofovir dipivoxil) to prevent the emergence of resistance and virological breakthrough. In patients receiving a potent drug with high genetic barrier to resistance (e.g. entecavir), or a less potent drug with high genetic barrier to resistance (e.g. adefovir dipivoxil) virological monitoring is required every three months and maintains longer than 48 weeks. The optimal management of these patients with partial virological response or suboptimal virological response at week 48 should be subjected to add another NUC without cross-resistance or IFN-α/ Peg IFN according to the treatment with the prior agent. The patients with complete virological response at week 48 the treatment may continue with the initial antiviral agent.
In patients with suboptimal virological response (HBV DNA≥4 log 10 copies/ml), switch to or addingon a drug without cross-resistance is recommended. Virological monitoring of these patients is required every three months and maintains at least 48 weeks. The period of virological monitoring can be prolonged to six months when the HBV DNA levels are undetectable. In patients with virological breakthrough after a complete virological response, the treatment regimen based on adding a drug without cross-resistance is recommended during any stage of treatment. The period of virological monitoring is required at a 3-month interval after the treatment adaptation.
Rescue combination therapy strategy
The majority of patients need long-term therapy with NUC rather than finite treatment to maintain the sustained virological response. The risk of virological resistance will increase as the time of treatment going. Along with the variety of NUC increased, the patterns of HBV resistance also become more complicated. In case of resistance to NUC, especially for the patients with decompensate liver cirrhosis, an appropriate rescue therapy should be initiated as soon as possible. Usually virological breakthrough appears prior to biochemical breakthrough, so the initiation of rescue therapy before the biochemical breakthrough can prevent the emergence of hepatitis flare and exacerbations of liver disease. To diminish the risk of engendering multidrug resistant variant, adding on another NUC without crossresistance is preferred option. 15, 16 The details of rescue strategies are explained as follows: a. Lamivudine resistance: Add adefovir dipivoxil or tenofovir dipivoxil. b. Adefovir dipivoxil resistance: If there is rtN236T mutation, add one of lamivudine, entecavir, and telbivudine; or switch to Truvada. If there is rtA181T/ V mutation, add entecavir or switch to Truvada. The safety of combination with tenofovir dipivoxil and entecavir is still need to clarify. c. Telbivudine resistance: Add adefovir dipivoxil or tenofovir dipivoxil (The safety of long-term combination therapy is still need to clarify.) d. Entecavir resistance: Add adefovir dipivoxil or tenofovir dipivoxil (The safety of combination therapy is still need to clarify.). e. Tenofovir dipivoxil resistance: To date, resistance to tenofovir dipivoxil has not been described. It is recommended that genotyping and phenotyping should be done in such cases by an expert laboratory to determine the cross-resistance profile. Adding one of entecavir, telbivudine, lamivudine, or entecavir is feasible (The safety of combination therapy is still need to clarify.) Combination therapy in co-infected patients with CHB In Chinese population, the HBsAg carrier rate is 7.18%, which is still among the high epidemic area in the world. Due to similar routes of transmission, HBV and hepatitis C virus (HCV), or human immunodeficiency virus (HIV) coinfection is also very common. In HBV/HCV, HBV/HIV co-infected patients, different strategies of combination therapy should be taken according to the specific characteristics of their diseases.
Treatment for HBV/HCV co-infected patients
Approximately 10 to 20% of CHB patients have coinfection with HCV. In HBV-infected patients, HCV co-infection accelerates liver disease progression and increases the incidence of liver cirrhosis, decompensate liver disease, and HCC. For most of the patients, the replication of HBV was suppressed by HCV due to interaction between the two viruses. The strategies of these co-infected patients should be formulated according to the levels of HBV DNA, HCV RNA, and serum ALT levels ( Table 2 ). There is a potential risk of HBV reactivation and liver disease progression after clearance of HCV that may release the suppression of HBV replication. Therefore, the monitoring of HBV DNA levels and relevant virological parameters is necessary during the treatment for HCV infection.
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Treatment for HBV/HIV co-infected patients
Approximately 6% to 13% of CHB patients have coinfection with HIV. In HBV-infected patients, HIV coinfection may increase HBV DNA levels and reduce the incidence of spontaneous HBeAg seroconversion, which may exacerbate liver disease and increase the liver disease-related mortality. In HBV/HIV co-infected patients, the selection of antiviral therapy regimens for HBV infection depends on the strategies of highly active antiretroviral therapy (HAART) for HIV infection. If the co-infected patients need to be treated simultaneously for both HIV and HBV, NUC for HBV antiviral therapy should be selected in the strategies of HAART such as the strategy which includes both tenofovir dipivoxil and lamivudine, or Truvada. In the patients receiving the strategy of HAART that includes lamivudine only for HBV infection, the risk of virological resistance should be monitored closely and the strategy should be changed if necessary. Lamivudine, tenofovir dipivoxil, or entecavir monotherapy may increase the risk of HIV resistance, so the strategy for patients with HBV infection should not include above-mentioned drugs, instead of which adefovir dipivoxil, telbivudine, or IFN-α can be selected if the patients don't need the HAART for HIV infection temporarily.
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A N T I -I N F L A M M A T O R Y A N D H E PAT O P R O T E C T I V E D R U G S I N COMBINED TREATMENT OF CHRONIC HEPATITIS B
T h e a p p l i c a t i o n o f a n t i -i n f l a m m a t o r y a n d hepatoprotective drugs in treatment of chronic hepatitis B had a long history. The anti-inflammatory and hepatoprotective drugs had played an important role in treatment of CHB until antiviral drugs were developed. At present, anti-inflammatory and hepatoprotective drugs mainly include glycyrrhizic acids, milk thistles, schisandra formulation and its derivatives, bicyclol (a monomeric compound produced by chemical synthesis), cell membrane protective agent, and antioxidant, etc. In recent years, more and more evidence reveals that the combination of antivirus drugs and anti-inflammatory and hepatoprotective drugs may be one of better treatment options of CHB.
Bicyclol in combined treatment of CHB
The efficacy and safety profiles of adefovir dipivoxil plus bicycle combination therapy regimen have been explored. This multi-centered, randomized, controlled clinical trial is to compare the efficacy of bicyclol tablet combined with adefovir dipivoxil and adefovir dipivoxil alone in treatment of CHB. 19 A total of 250 patients with CHB were randomly assigned to receive oral adefovir dipivoxil 10 mg, once daily, and oral bicyclol tablet 25 mg, tid (combination group, n = 125) or oral adefovir dipivoxil 10 mg alone, once daily (control group, n = 125). Both groups were treated for 48 weeks. AT week 48, HBV DNA detectable rate, HBeAg loss or seroconversion rate in combination group and control group were 34.4% and 31.7%, 29.5% versus 25.8%, and 20.5% versus 18.3%, respectively, without significant difference (P > 0.05). Serum ALT and AST in both groups significantly decreased, with reduction of 123.1 ± 25.6 U/L versus 100.1 ± 30.6 U/L, and 95.5 ± 23.6 U/L versus 85.0 ± 27.5 U/L, respectively (combination group versus control group) (P < 0.01). Normalization rate of serum ALT and AST in combination group were 78.7% and 68.7%, compared with 60% and 54.2% (P < 0.01). At the end of treatment, inflammatory necrosis score in both groups has been decreased. Moreover the reduction of Knodell score in combination group is significantly higher that that in control group (3.8 ± 2.9 and 2.4 ± 2.3, respectively) (P < 0.05). No drugs-related adverse events occurred in both groups. Thus, efficacy of adefovir dipivoxil combined with bicyclol in treatment of CHB was superior to adefovir dipivoxil alone, with improvement in liver function and histology. In addition, combination therapy had not negative influence on antiviral effect, but favorable safety.
Based on the above study, experts suggested that bicyclol combined with adefovir dipivoxil could inhibit HBV replication, and improve liver function and liver histology score. However, indication, course, evaluation index of efficacy, and long term outcome of combination of these two drugs need to be further determined.
Other hepatoprotective drugs in combined treatment of chronic hepatitis B
Chinese experts had assessed efficacy of glycyrrhizic acids in treatment of CHB by meta analysis. Results showed that glycyrrhizic acids could improve symptoms and signs in patients with CHB, and facilitate recovery of their liver function. But due to low evidence level of evidence-based medicine included by methodology in trials of meta analysis, the above results need further validation by randomized controlled trials with rigorous design and methodology of high quality. 20, 21 Results of several single center, small randomized, controlled trials comparing efficacy of milk thistles combined with interferon α in treatment of hepatitis B, which were published currently, showed that recovery of liver function in combination group was better than that of interferon α alone group.
22,23
Since no publication of related article was retrieved, the value of other hepatoprotective drugs in treatment of CHB need further research through well designed clinical trials.
I M M U N O M O D U L AT O R D R U G S I N COMBINATION THERAPY OF CHB
Immune system plays a vital role in control of HBV infection. Yet antiviral agents available today are not potential enough to rebuild effective anti-HBV immune. So physicians hope combination therapy of immunomodulators (ie. IFN-α, thymosinα-1, Thymopentin, interleukins, etc) may enhance the antiviral effect of other anti-HBV agents.
IFN-α in the combination therapy of CHB
Meta analysis showed the rates of HBV DNA negativity, HBeAg loss and HBsAg loss are37%, 33% and 7.8% for HBeAg positive patients who took conventional IFN-α. 24 So the response rate of monotherapy of conventional IFN-α is still not satisfactory. The HBeAg loss rate is only 32% for HBeAg positive CHB patients (87% Asians) using Peg-IFNα-2a monotherapy, according to the results of international, multi-centered, randomized and controlled clinical trial of PegIFN-α-2a, treated for 48 weeks and followed for 24 weeks.
25,26
Several clinical trials of IFN-α plus NUC therapy showed that combination therapy may bring higher rate of HBV DNA negativity and HBeAg seroconversion and lower rate of NUC resistance comparing with NUC monotherapy. [27] [28] [29] Yet these studies are not welldesigned RCT studies. Further studies are needed to verify this conclusion. Indications for combination therapy of IFN-α and NUC CHB patients with unsatisfactory response to IFN-α may be considered for NUC add-on therapy. Baseline HBeAg, HBsAg and HBV DNA levels and dynamics of these indices during IFN-α therapy may predict the sustained response to Patients treated with IFN-α may be considered for combination of NUC at week 24 according to the dynamics of HBeAg, HBsAg and HBV DNA levels. 33 a. HBeAg positive patients who have taken 24 weeks IFN-α therapy with HBV DNA ≥ 5 log 10 copies/ml, HBeAg ≥ 100 PEI U/ml or HBsAg ≥ 20 000 IU/ml should be considered for combination therapy with NUC. b. HBeAg negative patient who have taken 24 weeks IFN-α therapy with HBV DNA ≥ 5 log 10 copies/ml, and HBsAg decrease ≤1 log 10 IU/ml should be considered for combination therapy with NUC.
Re-evaluation of HBV DNA, HBeAg, HBsAg is recommended after 24 weeks combination therapy to decide future treatment.
Patients with unsatisfactory response to NUCs may also be considered for combination therapy with IFN-α. 
Regiments for combination therapy of IFN-α and NUC
Combination therapy of IFN-α and lamivudine
Previous studies showed combination therapy of IFN-α and NUCs may enhance the antiviral efficacy, when compared with IFN-α or NUCs monotherapy. PegIFN-α-2b treated patients who took lamivudine at week 4 and continued combination therapy for 52 weeks may have higher rate of HBeAg seroconversion at the end of 24 weeks follow-up. 28 Another study showed HBeAg negative CHB patients who took LAM and PegIFN-α-2b have preferable biochemical response and HBV resistance profile when compared with LAM monotherapy (biochemical response: 72.2% vs. 25%, virological breakthrough: 0 vs. 25%).
34 HBeAg positive patients who took PegIFN-α-2a and LAM combination therapy have 8% HBsAg seroconversion at week 48 and 30% at week 96.
35 Eight-hundred and fourteen HBeAg positive CHB patients were randomized to PegIFN-α-2a + placebo, PegIFN-α-2a + LAM, LAM monotherapy for 48 weeks and were followed for 24 weeks. At the end of follow-up, PegIFN-α-2a + placebo group and PegIFN-α-2a + LAM groups have preferable HBeAg seroconversion rates when compared with LAM monotherapy group (32%, 27% vs. 19%). And PegIFN-α-2a +placebo group and PegIFN-α-2a + LAM groups have more patients with HBV DNA≤10 4 copies/ml when compared with LAM monotherapy group (32%, 34% vs 22%). Patients took PegIFN-α-2a therapy (PegIFN-α-2a + placebo or LAM) have 6 patients achieved HBsAg seroconversion, while no patients in LAM monotherapy group achieved HBsAg seroconversion.
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Combination therapy of IFN-α and adefovir dipivoxil
Comparing with IFN-α-2b monotherapy, the study showed that combination of IFN α-2b and adefovir dipivoxil for 48 weeks may achieve preferable profile of HBV DNA negativity, HBeAg seroconversion and HBsAg seroconversion (86% vs 50%, 50% vs. 36%, 14% vs. 0%, respectively).
36 Combination therapy of PegIFN-α-2b and ADV for CHB patients may bring lower HBV DNA and HBsAg levels. When compared baseline, patents with combination therapy have significantly lower intrahepatic ccc DNA level.
37 One hundred and twenty HBeAg positive Chinese CHB patients were randomized to PegIFN-α-2a, PegIFN-α-2a + ADV, ADV for 48 weeks. At the end of treatment, PegIFN-α-2a alone group and PegIFN-α-2a + ADV group have preferable HBeAg loss when compared with ADV alone group (44.7%, 54.3% vs. 22.5%). And PegIFN-α-2a alone group and PegIFN-α-2a + ADV groups have more patients achieved HBeAg seroconversion when compared with ADV group ( 44.7%, 51.4% vs. 17.5%).
38 Seventeen percent patients taken combination therapy of PegIFN-α-2a and ADV for 48 weeks have HBsAg loss at the end of treatment. While patient were followed till 96 weeks, 22% patients lose HBsAg. 39 Four percent HBeAg positive patients who took combination therapy of PegIFN-α-2a and ADV at the end of 48 weeks treatment and 24% at the end of 96 weeks treatment, significantly higher than that of monotherapy.
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Combination therapy of IFN-α and telbivudine
Studies showed combination therapy of PegIFN and LdT may increase risk of peripheral neuropathy. [40] [41] [42] Combination of PegIFN and LdT should be prohibited.
Combination therapy of IFN-α and entecavir
Till now, no RCT studies about combination therapy of IFN-α and entecavir for CHB have been reported. Considering the preferable profile of lamivudine/ adefovir dipivoxil and IFN-α combination therapy, it is suggested the careful combination of entecavir and IFN-α may be considered for CHB patients in further study. Yet further large sample, multi-centered RCT studies are urged to verify this regimen.
Tα-1 in combination therapy of CHB
Immunomodulator besides IFN-α agent have also been used for combination therapy for CHB. Yet studies mainly focused on Tα-1 and less are reported about other immunomodulators.
In CHB patients, Tα-1 may enhance Th1 response, inhibit Th2 cytokines production and rebuild the balance of Th1/Th2, thus to help the clearance of HBV.
43 When Tα-1 is used in combination with IFN-α, it may promote the production of Th1 cytokines, and inhibit the Th2 cytokines induced by IFN-α.
44 So Tα-1 complements the effect of anti-HBV agents. And Tα-1 has nice safety profile in decade's clinical practice. Lim et al. reported a double-blind, randomized, p l a c e b o -c o n t r o l l e d s t u d y t o c o m p a r e I F N -α monotherapy with combination of IFN-α and Tα-1 in treatment of CHB patients. Results indicated that combination group has higher rate of HBeAg loss when compared with monotherapy group. 45 Mao et al. reported a meta analysis of combination therapy of IFN-α and Tα-1 for HBeAg positive CHB patients. In this meta analysis, total 535 cases from 7 RCT studies were enrolled. And study showed that combination therapy have preferable HBV DNA negativity, ALT normalization, HBeAg loss and HBeAg seroconversion at end of treatment and follow-up, when compared with IFN-α monotherapy. Combination therapy shows no extra adverse events when compared with IFN-α monotherapy.
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Combination therapies of Tα-1 and NUC mainly focus on lamivudine and adefovir dipivoxil. Zhang et al reported a meta-analysis compared between combination therapy of LAM + Tα-1 and LAM monotherapy in HBeAg positive CHB patients. In this meta analysis, total of 583 cases from 8 RCT studies were enrolled. And study showed that combination therapy have preferable HBV DNA response, ALT normalization and HBeAg seroconversion when compared with lamivudine monotherapy.
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Tα-1 complements the effect of anti-HBV agents. And available studies showed Tα-1 may enhance the efficacy of anti-HBV agents and has nice safety profile in decade's clinical practice. Yet large-sale, multicentered, randomized and controlled studies are needed to verify Tα-1 use in combination therapy of CHB. As for other immunomodulators, no suggestions can be made for the deficiency of evidence and further studies are urged.
